Lexaria Bioscience appoints Nelson Cabatuan as CFO effective March 14, 2024

Lexaria Bioscience Corp.

Nelson Cabatuan, age 46, replaces temporary outsourced CFO services from NOW CFO.
Base annual salary of US$198,000 with agreed annual increases of US$12,000 for first two years.
Option grant of up to 200,000 common shares vested over three years; performance bonuses up to 35-50% of base.
Exit compensation: upon sale of affiliate, 0.5%-1.0% of gross sale value; change-of-control triggers 12-14 months base salary.
Cabatuan brings over 15 years biotech finance experience; previously SVP at Rain Oncology and VP at Rigel Pharmaceuticals.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Nelson Cabatuan

Chief Financial Officer

LEXX · Lexaria Bioscience Corp.

Effective: 2024-03-14
Filed: March 15, 2024, 7:59 PM ET

Effective March 14, 2024, Nelson Cabatuan, age 46, has been appointed to the position of Chief Financial Officer of Lexaria Bioscience Corp.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Nelson Cabatuan was appointed as Chief Financial Officer at Lexaria Bioscience Corp..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

Effective March 14, 2024, Nelson Cabatuan, age 46, has been appointed to the position of Chief Financial Officer of Lexaria Bioscience Corp.

View on SEC.gov

Lexaria Bioscience Corp. filing history →

Source: SEC EDGAR

accession 0001640334-24-000410

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.